Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Non-Current Deferred Tax Liability (2018 - 2021)

Historic Non-Current Deferred Tax Liability for Kyntra Bio (KYNB) over the last 4 years, with Q4 2021 value amounting to $9.2 million.

  • Kyntra Bio's Non-Current Deferred Tax Liability rose 595.97% to $9.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was $9.2 million, marking a year-over-year increase of 595.97%. This contributed to the annual value of $9.2 million for FY2021, which is 595.97% up from last year.
  • According to the latest figures from Q4 2021, Kyntra Bio's Non-Current Deferred Tax Liability is $9.2 million, which was up 595.97% from $9.1 million recorded in Q3 2021.
  • In the past 5 years, Kyntra Bio's Non-Current Deferred Tax Liability ranged from a high of $9.2 million in Q4 2021 and a low of $8.1 million during Q4 2018
  • Its 4-year average for Non-Current Deferred Tax Liability is $8.8 million, with a median of $8.8 million in 2019.
  • In the last 5 years, Kyntra Bio's Non-Current Deferred Tax Liability soared by 952.32% in 2019 and then plummeted by 267.03% in 2020.
  • Quarter analysis of 4 years shows Kyntra Bio's Non-Current Deferred Tax Liability stood at $8.1 million in 2018, then rose by 9.52% to $8.9 million in 2019, then fell by 2.67% to $8.7 million in 2020, then grew by 5.96% to $9.2 million in 2021.
  • Its Non-Current Deferred Tax Liability was $9.2 million in Q4 2021, compared to $9.1 million in Q3 2021 and $9.0 million in Q2 2021.